Refine
Year of publication
Document Type
- Preprint (693)
- Article (591)
- Working Paper (10)
- Conference Proceeding (3)
- Part of Periodical (2)
- Part of a Book (1)
- Report (1)
Has Fulltext
- yes (1301)
Is part of the Bibliography
- no (1301)
Keywords
- Heavy Ion Experiments (20)
- Hadron-Hadron Scattering (11)
- Hadron-Hadron scattering (experiments) (11)
- LHC (9)
- Heavy-ion collision (6)
- ALICE experiment (4)
- Collective Flow (4)
- Hepatocellular carcinoma (4)
- Jets (4)
- Quark-Gluon Plasma (4)
- ALICE (3)
- COVID-19 (3)
- Cirrhosis (3)
- Gene expression (3)
- HIV (3)
- Heavy Ions (3)
- Immunology (3)
- Inflammation (3)
- Jets and Jet Substructure (3)
- Liver diseases (3)
- cancer (3)
- child (3)
- pp collisions (3)
- Antitrust (2)
- Beauty production (2)
- Bone density (2)
- Charm physics (2)
- Consumer Welfare (2)
- Diagnostic markers (2)
- Ewing sarcoma (2)
- Experimental nuclear physics (2)
- Experimental particle physics (2)
- HCC (2)
- Heavy Quark Production (2)
- Lepton-Nucleon Scattering (experiments) (2)
- Literaturtheorie (2)
- MLL (2)
- Mouse models (2)
- Oncology (2)
- Osteoporosis (2)
- Particle Correlations and Fluctuations (2)
- Particle and resonance production (2)
- Particle correlations and fluctuations (2)
- Pb–Pb collisions (2)
- Psychiatric disorders (2)
- QCD (2)
- Relativistic heavy-ion collisions (2)
- SARS-CoV-2 (2)
- Single electrons (2)
- Sustainability (2)
- aortic stenosis (2)
- biomarker (2)
- children (2)
- cirrhosis (2)
- habitat destruction (2)
- hematopoietic stem cell transplantation (2)
- hepatitis C virus (2)
- invasive fungal disease (2)
- lung cancer (2)
- proteomics (2)
- soft tissue sarcoma (2)
- sphingolipids (2)
- web archiving (2)
- 15-PGDH (1)
- 8 weeks (1)
- 900 GeV (1)
- ACURATE neo (1)
- AKI (1)
- ALICE detector (1)
- ALK-rearranged NSCLC (1)
- ALL (1)
- AML (1)
- APRI (1)
- Accelerators & Beams (1)
- Accelerators & storage rings (1)
- Actin (1)
- Active middle ear implants (1)
- Acute coronary syndrome (1)
- Acute myeloid leukemia (1)
- Adenylyl cyclase (1)
- Amino acid analysis (1)
- Anandamide (1)
- Angiogenesis (1)
- Animal models (1)
- Anti-nuclei (1)
- Antibiotic steward-ship (1)
- Antibiotic therapy (1)
- Antibiotics (1)
- Antiretroviral therapy (1)
- Antiretrovirals (1)
- Antiviral therapy (1)
- Apoptosis (1)
- Artificial Intelligence (1)
- Ataxia-telangiectasia (1)
- Atomic & molecular beams (1)
- Atomic, Molecular & Optical (1)
- Atoms (1)
- Atrial fibrillation (1)
- Auditory system (1)
- Autologous stem cell transplantation (1)
- Autorschaft (1)
- BFIS (1)
- BRAF (1)
- Backscattering (1)
- Beam loss (1)
- Biodiversity Data (1)
- Biomarker (1)
- Biomarkers (1)
- Biomass monitoring (1)
- Biomonitoring (1)
- Bioprocess automation (1)
- Bipolar disorder (1)
- Blood plasma (1)
- Bone conduction devices (1)
- Bone diseases, Metabolic (1)
- Boosted Jets (1)
- Botanical Collections (1)
- Breast cancer (1)
- Breast tumors (1)
- Buprestidae (1)
- C6 ceramide (1)
- CCL2 (1)
- CEP68 (1)
- COMT (1)
- COVID 19 (1)
- CRISPR/Cas (1)
- CT (1)
- CT dual-energy computed tomography (1)
- CVID (1)
- Cancer (1)
- Cancer chemotherapy (1)
- Cancer detection and diagnosis (1)
- Cancer treatment (1)
- Canopy height model (1)
- Cardiac hypertrophy (1)
- Cardiac surgery (1)
- Cardiac troponin (1)
- Cardiology (1)
- Cardiovascular biology (1)
- Cardiovascular disease risk (1)
- Cardiovascular diseases (1)
- Cell binding (1)
- Cell membranes (1)
- Cell staining (1)
- Centrality Class (1)
- Centrality Selection (1)
- Cerambycidae (1)
- Charge fluctuations (1)
- Charge-transfer collisions (1)
- Checkpoint inhibitor (1)
- Chronic hepatitis C (1)
- Circular accelerators (1)
- Cleanliness level (1)
- Clinical Trials and Observations (1)
- Clinical genetics (1)
- Collective Flow, (1)
- Colon capsule endoscopy (1)
- Colorectal cancer (1)
- Comparison with QCD (1)
- Complementation rate (1)
- Computer-aided drug design (1)
- Congenital anomalies (1)
- Consensus statement (1)
- Conservation (1)
- CuveWaters (1)
- C‐reactive protein (1)
- DNA sequence analysis (1)
- DST (1)
- Data sharing (1)
- Denervation (1)
- Diauxic effects (1)
- Differentiation (1)
- Digestive system procedures (1)
- Digitization (1)
- Dilated cardiomyopathy (1)
- Direct Acting Antivirals (DAA) (1)
- Drug susceptibility testing (1)
- Dual-energy computed tomography (1)
- ESBL (1)
- ESG (1)
- ETP-ALL (1)
- Early goal-directed therapy (1)
- Eicosanoids (1)
- Electroantennography (1)
- Electron-pion identification (1)
- Electronic transitions (1)
- Electroweak interaction (1)
- Elliptic flow (1)
- Embryos (1)
- Empirische Ästhetik (1)
- European Society for Immunodeficiencies (ESID) (1)
- Extended donor criteria (1)
- F508del homozygous (1)
- FDM (1)
- FGFR (1)
- FIB-4 (1)
- FLT3 (1)
- Fatty acids (1)
- Fatty liver (1)
- Femtoscopy (1)
- Fibre/foam sandwich radiator (1)
- Fibrosis (1)
- Fibrotest (1)
- Filovirus cell entry; attachment factors redundancy; SH-SY5Y cell line; host–pathogen interactions (1)
- Flow cytometry (1)
- Forschung (1)
- Forschungsdatenmanagement (1)
- Functional clustering (1)
- G-protein-coupled receptors (1)
- GWAS (1)
- Gastric cancer (1)
- Genetic causes of cancer (1)
- Genetic testing (1)
- Genetics (1)
- Genome editing (1)
- German PID-NET registry (1)
- Gomphus flavipes (1)
- Guanine nucleotide exchange factors (1)
- Guanosine triphosphatase (1)
- Gαq/11 (1)
- HBT (1)
- HBV (1)
- HCV (1)
- HDAC4 (1)
- HIF1α (1)
- HIPPO signalling (1)
- HIV-1 (1)
- HNO (1)
- Hadron production (1)
- Hadron-Hadron Scattering Heavy (1)
- Hadron-hadron interactions (1)
- Hals-Nasen-Ohren-Heilkunde (1)
- Haploidentical stem cell transplantation (1)
- Hard Scattering (1)
- Health policy (1)
- Heart (1)
- Heavy Ion Experiment (1)
- Heavy flavor production (1)
- Heavy flavour production (1)
- Heavy ions (1)
- Heavy-flavour decay muons (1)
- Heavy-flavour production (1)
- Heavy-ion collisions (1)
- Hepatitis B virus (1)
- Hepatitis C (1)
- Hepatitis C virus (1)
- Hepatotoxicity (1)
- Herbaria (1)
- High-dose chemotherapy (1)
- Histology (1)
- Homeostasis (1)
- Hsp70 (1)
- Human genetics (1)
- Hypertension (1)
- Hypoxic responses (1)
- IHC (1)
- IWRM (1)
- Icelandic Family Sagas (1)
- IgG substitution therapy (1)
- Immunogenetics (1)
- Inclusive spectra (1)
- Incomplete colonoscopy (1)
- Infection (1)
- Intensity interferometry (1)
- Intensive care unit (1)
- International Law (1)
- Internationales Recht (1)
- Interventional oncological treatment (1)
- Intravenous injections (1)
- Invariant Mass Distribution (1)
- Ionisation energy loss (1)
- Ions (1)
- Jet Physics (1)
- Jet Substructure (1)
- KDIGO (1)
- KIR (1)
- Konstitutionalismus (1)
- Kupffer cells (1)
- LCH (1)
- Landesinitiative (1)
- Landesinitiative für Forschungsdatenmanagement (1)
- Langerhans cell histiocytosis (1)
- Laser interstitial thermal therapy (1)
- Lehre (1)
- Lenalidomide (1)
- Libellen (1)
- Library screening (1)
- Literarischer Stil (1)
- Literaturwissenschaft (1)
- Liver (1)
- Liver cancer (1)
- Liver cirrhosis (1)
- Liver enzymes (1)
- Liver fibrosis (1)
- Liver transplantation (1)
- Long non-coding RNAs (1)
- Low & intermediate-energy accelerators (1)
- Low volume prep (1)
- Luciferase (1)
- Lymphoid Neoplasia (1)
- Lyrik (1)
- M. Intracellulare (1)
- M. avium (1)
- M. avium complex (1)
- M. chimaera (1)
- MALAT1 (1)
- MRP4 (1)
- Macrophages (1)
- Marker genes (1)
- Material budget (1)
- Mechanisms of disease (1)
- Mena/VASP (1)
- Mesenchymal stem cells (1)
- Metabolic shift (1)
- Metabolism (1)
- Microbiology and Infectious Disease (1)
- Microglial cells (1)
- Microwave ablation (1)
- Mid-rapidity (1)
- Minimal residual disease (1)
- Minimum Bias (1)
- Mixed hearing loss (1)
- Mongolia (1)
- Monochamus galloprovincialis (1)
- Monte Carlo (1)
- Mortality (1)
- Moviprep (1)
- Multi-Parton Interactions (1)
- Multi-nucleated cardiomyocytes (1)
- Multi-stakeholder approach (1)
- Multi-strange baryons (1)
- Multi-wire proportional drift chamber (1)
- Multidrug-resistant organisms (1)
- Multiple myeloma (1)
- Multivariate analysis (1)
- Muscle atrophy (1)
- Musikästhetik (1)
- Mutation databases (1)
- Myocardial infarction (1)
- NCoR1 (1)
- NFDI (1)
- NK cells (1)
- NMR spectroscopy (1)
- NOTCH1 (1)
- NTM (1)
- Nachhaltigkeit (1)
- Namibia (1)
- Nationale Forschungsdateninfrastruktur (1)
- Neural network (1)
- Neurons (1)
- Neuroästhetik (1)
- Non-tuberculous mycobacteria (1)
- Nuclear astrophysics (1)
- Nuclear modification factor (1)
- Nuclear physics of explosive environments (1)
- Nuclear reactions (1)
- Nucleus accumbens (1)
- ORL (1)
- Oncogenes (1)
- Online monitoring (1)
- Ophiogomphus cecilia (1)
- Optogenetics (1)
- Organ allocation (1)
- Orphan disease (1)
- Osteoporotic fractures (1)
- Otorhinolaryngology (1)
- Ovarian cancer (1)
- PD-L1 (1)
- PGE2 (1)
- PID prevalence (1)
- PKA (1)
- PKD (1)
- PKD/IC (1)
- PRRT2 (1)
- PYTHIA (1)
- Pancreas transplantation (1)
- Parallelisation (1)
- Particle and Resonance Production (1)
- Pb–Pb (1)
- Periodontal disease (1)
- Periodontal therapy (1)
- Perturbative methods (1)
- Phaenops cyanea (1)
- Phantoms (imaging) (1)
- Phospho-soda (1)
- Phosphorylation (1)
- Photon counting (1)
- PillCamColon2 (1)
- Plasminogen (1)
- Platelets (1)
- Polyps (1)
- Portal veins (1)
- Production Cross Section (1)
- Properties of Hadrons (1)
- Prostaglandin (1)
- Proton–proton (1)
- Pulsed SILAC (1)
- QGP (1)
- Quark Deconfinement (1)
- Quark Gluon Plasma (1)
- Quark Production (1)
- Quark gluon plasma (1)
- Quarkonium (1)
- RDM (1)
- RNA (1)
- RNA, long noncoding (1)
- RNA-binding proteins (1)
- Radiative capture (1)
- Random forest (1)
- Rapidity Range (1)
- Regression analysis (1)
- Rehabilitation (1)
- Rejection (1)
- Relapse (1)
- Relativistic heavy ion physics (1)
- Renal cell carcinoma (1)
- Research (1)
- Research Article (1)
- Research Data Management (1)
- Research Infrastructure (1)
- Residency (1)
- Resolution Parameter (1)
- Riftia pachyptila (1)
- S. cerevisiae (1)
- SARS CoV 2 (1)
- SARS-CoV‑2 pandemic (1)
- SARS-CoV‑2-Pandemie (1)
- SCCHN (1)
- SENP (1)
- SKI II (1)
- STED superresolution (1)
- SUMO (1)
- SVR (1)
- Safety (1)
- Sarcopenia (1)
- Scattering of atoms, molecules, clusters & ions (1)
- Scattering theory (1)
- Second-line treatment (1)
- Semantics (1)
- Sepsis-bundle (1)
- Sequence (1)
- Shake flask (1)
- Single muons (1)
- Single-cell RNA-sequencing (1)
- Small molecules (1)
- Specialist training (1)
- Spectrin (1)
- Sphingolipids (1)
- Stem cells (1)
- Surgery (1)
- Surgical and invasive medical procedures (1)
- Surgical oncology (1)
- Survival (1)
- Sustained virological response (SVR) (1)
- Systematic Uncertainty (1)
- Systemic treatment (1)
- T-ALL (1)
- TACE (1)
- TAVR (1)
- TGF-beta (1)
- TOR signalling (1)
- TP53 mutation status (1)
- TR (1)
- Targeted therapy (1)
- Taxonomy (1)
- Teaching (1)
- Technical data (1)
- Thrombosis (1)
- Thromboxane (1)
- Time Projection Chamber (1)
- Tomography (x-ray computed) (1)
- Tracking (1)
- Transarterial chemoembolization (1)
- Transcriptome analysis (1)
- Transferases (1)
- Transient elastography (1)
- Transition radiation detector (1)
- Transverse momentum (1)
- Trigger (1)
- Trousseau’s syndrome (1)
- Type 2 diabetes (1)
- Tyrosine kinase inhibitor mTOR inhibition (1)
- UAV (1)
- Ubiquitination (1)
- University hospitals (1)
- Universitätskliniken (1)
- VRE (1)
- Vector Boson Production (1)
- Veins (1)
- Vesicles (1)
- Viral load (1)
- Weiterbildung (1)
- Wettbewerbsrecht (1)
- X-ray crystallography (1)
- Xenon-based gas mixture (1)
- Yellow fluorescent protein (1)
- a-induced reactions (1)
- accessory proteins (1)
- acoustic radiation force impulse imaging (1)
- activation (1)
- acute coronary syndrome (1)
- acute leukemia (1)
- acute lymphoblastic leukemia (1)
- adenocarcinoma (1)
- adenosine receptors (1)
- aesthetic reward (1)
- age (1)
- agriculture (1)
- alcoholic hepatitis (1)
- allogeneic stem cell transplantation (1)
- amino acids (1)
- angiopoietin-like 3 (ANGPTL3) (1)
- anti-EGFR therapy (1)
- antibiotic therapy (1)
- antibodies (1)
- antiepileptic drugs (1)
- antifungal combination therapy (1)
- antifungal therapy (1)
- antimicrobial stewardship (1)
- antiviral therapy (1)
- arachidonate 12/15-lipoxygenase (Alox12/15) (1)
- architecture (1)
- ascites (1)
- atherosclerosis (1)
- atrial fibrillation (1)
- atrophy (1)
- autophagy (1)
- b-cell lymphomas (1)
- bacteremia (1)
- bendamustine (1)
- blood (1)
- bone marrow metastasis (1)
- bone metastasis (1)
- cAMP (1)
- cART (1)
- cancer surveillance (1)
- carbapenem resistance (1)
- cardiac I/R injury (1)
- cardiac remodeling (1)
- cell differentiation (1)
- cell heterogeneity (1)
- cell-free protein synthesis (1)
- centrosome (1)
- centrosome linker (1)
- ceramides (1)
- chemoembolization (1)
- chemorefractory metastatic colorectal cancer (1)
- chemotherapy regimen (1)
- children and adolescents (1)
- chills (1)
- chimeric antigen receptor t-cell therapy (1)
- chimeric antigen receptors (1)
- cholestasis (1)
- chromosomal translocations (1)
- chronic kidney disease (1)
- chronic viral hepatitis (1)
- co-infection (1)
- cohort study (1)
- computed tomography (1)
- confidence interval (1)
- confirmatory factor analysis (1)
- constitutionalisation (1)
- constitutionalism (1)
- coronary disease (1)
- critical care unit (1)
- critical ill patients (1)
- cutaneous T cell lymphoma (1)
- cystic fibrosis (1)
- dE/dx (1)
- damage detection (1)
- decision aids (1)
- demand-responsive approach (1)
- desmoplastic small round cell tumor (1)
- detector (1)
- dihydroceramide (1)
- dihydroceramides (1)
- direct-acting antivirals (1)
- disease progression (1)
- drone (1)
- eNPP2 (1)
- enrichment (1)
- entity and event extraction (1)
- epigenomics (1)
- experimental results (1)
- extraskeletal (1)
- familial infantile epilepsy (1)
- fatigue testing (1)
- fibrocytes (1)
- fibrosis (1)
- fibrotest (1)
- fine spatial resolution remote sensing (1)
- first-time shoulder dislocation (1)
- fixed-links modeling (1)
- fluid intelligence (1)
- fumonisin B1 (1)
- gap junction protein alpha 4-genotype (1)
- genetic generalized epilepsy (1)
- germ cell tumors (1)
- glass fiber reinforced materials (1)
- glecaprevir (1)
- glioblastoma (1)
- global change (1)
- graft rejection (1)
- head-and-neck cancer (1)
- heart failure (1)
- heavy ion experiments (1)
- hematopoietic cell transplantation (1)
- hemiplegic migraine (1)
- hepatic fibrosis (1)
- hepatic tumor (1)
- hepatitis C (1)
- hepatitis c (1)
- herbarium (1)
- high-dose chemotherapy (1)
- histology (1)
- homoarginine (1)
- host-microbe interaction (1)
- human knockout model (1)
- hypertension, pulmonary (1)
- idiopathic pulmonary fibrosis (1)
- immobilization in external rotation and abduction (1)
- immune checkpoint inhibitor (ICI) (1)
- immunohistochemistry (1)
- immunoprecipitation (1)
- immunotherapy (1)
- infection (1)
- infection control (1)
- infections (1)
- inflammatory markers (1)
- insulin resistance (1)
- interferon regulatory factor 9 (IRF9) (1)
- international legal theory (1)
- intraperitoneal therapy (1)
- intrinsically disordered region (1)
- ischemic type biliary lesions (1)
- knockout mouse (1)
- lamotrigine (1)
- land use (1)
- leukapheresis (1)
- leukemia (1)
- levetiracetam (1)
- lipoxin A4 (1)
- liver (1)
- liver abscess (1)
- liver cirrhosis (1)
- liver transplantation (1)
- long non-coding RNA (1)
- lung disease phenotype (1)
- lung function (1)
- lymphoma (1)
- l‐arginine:glycine amidinotransferase (1)
- maintenance therapy (1)
- malignancy (1)
- mass spectrometry (1)
- metastasis (1)
- methyltransferases (1)
- molecular characteristics (1)
- multi-resources mix (1)
- multidrug resistance (1)
- naturalization (1)
- neovascularization, physiologic (1)
- neuroaesthetics (1)
- neutralizing antibodies (1)
- neutropenia (1)
- nomadic lifestyles (1)
- non-ST-segment elevation acute coronary syndrome (1)
- non-invasive fibrosis assessment (1)
- non-neutropenic episode (1)
- nonstructural proteins (1)
- odds ratio (1)
- oral narratives (1)
- orthopic liver transplantation (1)
- outcome (1)
- ovary (1)
- p97 (1)
- parliament libraries (1)
- pediatric solid tumors (1)
- performativity (1)
- peritoneal carcinomatosis (1)
- pharmacoresistance (1)
- phenotype/genotype relation (1)
- phenotypic spectrum (1)
- pibrentasvir (1)
- piloerection (1)
- plant diversity (1)
- plant height (1)
- pneumonia (1)
- poetic language (1)
- point shear wave elastography (1)
- precision medicine (1)
- pressurized intraperitoneal aerosol chemotherapy (PIPAC) (1)
- primary biliary cirrhosis (1)
- primary immunodeficiency (1)
- primary immunodeficiency (PID) (1)
- primary sclerosing cholangitis (1)
- prognostic biomarker (1)
- quark gluon plasma (1)
- radar-based structural health monitoring (1)
- radio sensitivity (1)
- rain- and floodwater harvesting (1)
- rangeland ecosystems (1)
- rats (1)
- re-exposure (1)
- rechallenge (1)
- registry for primary immunodeficiency (1)
- reintroduction (1)
- resolution of inflammation (1)
- retrospective trial (1)
- risk assessment (1)
- rituximab (1)
- rootletin (1)
- rural-urban migration (1)
- sanitation (1)
- sarcoma (1)
- screening routine (1)
- semantic content analysis (1)
- sepsis (1)
- sequential ALK-inhibitor therapy (1)
- sex (1)
- short-chain ceramide (1)
- shortening of treatment (1)
- shoulder instability (1)
- shoulder stabilization (1)
- skeletal muscle (1)
- skin (1)
- social Web (1)
- solid tumor (1)
- sorafenib (1)
- specialized pro-resolving lipid mediators (SPMs) (1)
- spectra (1)
- sphinganine 1-phosphate (1)
- sphingolipid (1)
- sphingosine 1-phosphate (1)
- sphingosine kinase (1)
- sphingosine-1-phosphate (1)
- spike protein (1)
- steppe ecosystem (1)
- stopping rule (1)
- structural proteins (1)
- structure-from-motion photogrammetry (1)
- sulfur-oxidizing symbiont (1)
- symbiosis (1)
- tense switches (1)
- testis (1)
- text analysis (1)
- tomography (1)
- topic detection (1)
- transcatheter aortic valve replacement (1)
- transdisciplinarity (1)
- transfemoral (1)
- transient elastography (1)
- translocation partner genes (1)
- transmission (1)
- treatment (1)
- tumor microenvironment (TME) (1)
- type I interferons (IFNs) (1)
- tyrosine kinase inhibitor (TKI) (1)
- upper gastrointestinal cancer (1)
- valproic acid (1)
- variants of concern (1)
- vascular calcification (1)
- vemurafenib (1)
- versican (VCAN) (1)
- web crawler (1)
- whole-genome sequencing (1)
- wildlife mobility (1)
- wind turbine blades (1)
- working memory capacity (1)
- x-ray techniques (1)
- Ästhetik (1)
- γ-spectroscopy (1)
- гепатит С (1)
- правила прекращения лечения (1)
- противовирусные препараты прямого действия (ПППД) (1)
- сокращение лечения (1)
- устойчивый вирусологический ответ (УВО) (1)
- √sN N = 2.76 TeV (1)
Institute
- Physik (1086)
- Frankfurt Institute for Advanced Studies (FIAS) (961)
- Informatik (924)
- Medizin (160)
- Biowissenschaften (7)
- ELEMENTS (7)
- Biochemie, Chemie und Pharmazie (6)
- Sustainable Architecture for Finance in Europe (SAFE) (6)
- Wirtschaftswissenschaften (6)
- Geowissenschaften (5)
Objective: Phenotypic (Sensititre Myco, pDST) and genotypic drug susceptibility testing (GenoType NTM DR, gDST) in M. avium complex (MAC) have become available as standardized assays, but comparable data is needed. This study aimed to investigate the phenotypic and genotypic drug susceptibility patterns in MAC clinical isolates.
Methods: Overall, 98 isolates from 85 patients were included. pDST and gDST were performed on all isolates and results compared regarding specificity and sensitivity using pDST as a reference method. The impact of drug instability on pDST results was studied using a biological assay over 14 days. In addition, the evolution of antimicrobial resistance was investigated in sequential isolates of 13 patients.
Results: Macrolide resistance was rare, 1.2% (95% CI 0.7–7.3) of isolates in the base cohort. No aminoglycoside resistances were found, but 14.1% of the studied isolates (95% CI 7.8–23.8) showed intermediate susceptibility. The GenoType NTM DR identified two out of four macrolide-resistant isolates. Antibiotic stability was demonstrated to be poor in rifampicin, rifabutin, and doxycycylin.
Conclusions: pDST results in NTM for unstable antibiotics must be interpreted with care. A combination of pDST and gDST will be useful for the guidance of antimicrobial therapy in MAC-disease.
Tumor progression largely depends on the presence of alternatively polarized (M2) tumor-associated macrophages (TAMs), whereas the classical M1-polarized macrophages can promote anti-tumorigenic immune responses. Thus, selective inhibition of M2-TAMs is a desirable anti-cancer approach in highly resistant tumor entities such as hepatocellular carcinoma (HCC) or breast cancer. We here examined whether a peptide that selectively binds to and is internalized by in vitro-differentiated murine M2 macrophages as compared to M1 macrophages, termed M2pep, could be used to selectively target TAMs in HCC and breast carcinoma. We confirmed selectivity of M2pep for in vitro M2 polarized macrophages. Upon incubation of suspended mixed 4T1 tumor cells with M2pep, high amounts of the TAMs were found to be associated with M2pep, whereas in mixed tumor cell suspensions from two HCC mouse models, M2pep showed only low-degree binding to TAMs. M2pep also showed low-degree targeting of liver macrophages. This indicates that the TAMs in different tumor entities show different targeting of M2pep and that M2pep is a very promising approach to develop selective M2-TAM-targeting in tumor entities containing M2-TAMs with significant amounts of the so far elusive M2pep receptor(s).
The Eastern Steppe of Mongolia is one of the world's largest mostly intact grassland ecosystems and is characterised by a close coupling of societal and natural processes. In this ecosystem, mobility is one of the key characteristics of wildlife and human societies alike. The current economic development of Mongolia is accompanied by extensive societal transformation and changes in nomadic lifestyles, which potentially affects the unique steppe ecosystem and its biodiversity. The changing lifestyles are mainly characterised by rural-urban migration, resulting in reduced mobility of herders and their livestock, and presumably affecting wildlife. The question is how mobility can be fostered under these transformation processes. Time is pressing as a new generation is born which is growing up in urban environments and with new skill sets but a potential loss of the tight connection to nature and the nomadic lifestyle.
Chromosomal rearrangements of the human MLL (mixed lineage leukemia) gene are associated with high-risk infant, pediatric, adult and therapy-induced acute leukemias. We used long-distance inverse-polymerase chain reaction to characterize the chromosomal rearrangement of individual acute leukemia patients. We present data of the molecular characterization of 1590 MLL-rearranged biopsy samples obtained from acute leukemia patients. The precise localization of genomic breakpoints within the MLL gene and the involved translocation partner genes (TPGs) were determined and novel TPGs identified. All patients were classified according to their gender (852 females and 745 males), age at diagnosis (558 infant, 416 pediatric and 616 adult leukemia patients) and other clinical criteria. Combined data of our study and recently published data revealed a total of 121 different MLL rearrangements, of which 79 TPGs are now characterized at the molecular level. However, only seven rearrangements seem to be predominantly associated with illegitimate recombinations of the MLL gene (~ 90%): AFF1/AF4, MLLT3/AF9, MLLT1/ENL, MLLT10/AF10, ELL, partial tandem duplications (MLL PTDs) and MLLT4/AF6, respectively. The MLL breakpoint distributions for all clinical relevant subtypes (gender, disease type, age at diagnosis, reciprocal, complex and therapy-induced translocations) are presented. Finally, we present the extending network of reciprocal MLL fusions deriving from complex rearrangements.
Nuclear factor of activated T-cells (NFAT) and NF-kB pathway associated processes are involved in the pathogenesis of various inflammatory disorders, for example, periodontal disease. The activation of these pathways is controlled by the regulator of calcineurin 1 (RCAN1). The aim of this study was to elucidate the role of RCAN1 in periodontal disease. Healthy and inflamed periodontal tissues were analyzed by immunohistochemistry and immunofluorescence using specific rabbit polyclonal anti-RCAN1 antibodies. For expression analysis human umbilical vein endothelial cells (HUVEC) were used. HUVEC were incubated for 2 h with Vascular Endothelial Growth Factor (VEGF) or with wild type and laboratory strains of Porphyromonas gingivalis (P. gingivalis). Expression analysis of rcan1 and cox2 was done by real time PCR using specific primers for rcan1.4 and cox2. The expression of rcan1 was found to be significantly suppressed in endothelial cells of chronically inflamed periodontal tissues compared to healthy controls. Rcan1 and cox2 were significantly induced by VEGF and wild type and laboratory P. gingivalis strains. Interestingly, the magnitude of the rcan1 and cox2 induction was strain dependent. The results of this study indicate that RCAN1 is suppressed in endothelial cells of chronically inflamed periodontal tissues. During an acute infection, however, rcan1 seems to be upregulated in endothelial cells, indicating a modulating role in immune homeostasis of periodontal tissues.
Purpose: Advanced Ewing sarcomas have poor prognosis. They are defined by early relapse (<24 months after diagnosis) and/or by metastasis to multiple bones or bone marrow (BM). We analyzed risk factors, toxicity and survival in advanced Ewing sarcoma patients treated with the MetaEICESS vs. EICESS92 protocols.
Design: Of 44 patients, 18 patients were enrolled into two subsequent MetaEICESS protocols between 1992 and 2014, and compared to outcomes of 26 advanced Ewing sarcoma patients treated with EICESS 1992 between 1992 and 1996. MetaEICESS 1992 consisted of induction chemotherapy, whole body imaging directed radiotherapy to the primary tumor and metastases, tandem high-dose chemotherapy and autologous rescue. In MetaEICESS 2007 this treatment was complemented by allogeneic stem cell transplantation. EICESS 1992 comprised induction chemotherapy, local therapy to the primary tumor only followed by consolidation chemotherapy.
Results: In MetaEICESS 8/18 patients survived in complete remission vs. 2/26 in EICESS 1992 (p<0.05). Survival did not differ between MetaEICESS 2007 and MetaEICESS 1992. Three MetaEICESS patients died of complications, all in MetaEICESS 1992. After exclusion of patients succumbing to treatment related complications (n=3), 7/10 patients survived without BM involvement, in contrast to 0/5 patients with BM involvement. This was confirmed in a multivariate analysis. There was no correlation between BM involvement and the number of metastases at diagnosis.
Conclusion: The MetaEICESS protocols yield long-term disease-free survival in patients with advanced Ewing sarcoma. Allogeneic stem cell transplantation was not associated with increased death of complications. Bone marrow involvement is a risk factor distinct from multiple bone metastases.
Transcription factors can serve as links between tumor microenvironment signaling and oncogenesis. Interferon regulatory factor 9 (IRF9) is recruited and expressed upon interferon stimulation and is dependent on cofactors that exert in tumor-suppressing or oncogenic functions via the JAK-STAT pathway. IRF9 is frequently overexpressed in human lung cancer and is associated with decreased patient survival; however, the underlying mechanisms remain to be elucidated. Here, we used stably transduced lung adenocarcinoma cell lines (A549 and A427) to overexpress or knockdown IRF9. Overexpression led to increased oncogenic behavior in vitro, including enhanced proliferation and migration, whereas knockdown reduced these effects. These findings were confirmed in vivo using lung tumor xenografts in nude mice, and effects on both tumor growth and tumor mass were observed. Using RNA sequencing, we identified versican (VCAN) as a novel downstream target of IRF9. Indeed, IRF9 and VCAN expression levels were found to be correlated. We showed for the first time that IRF9 binds at a newly identified response element in the promoter region of VCAN to regulate its transcription. Using an siRNA approach, VCAN was found to enable the oncogenic properties (proliferation and migration) of IRF9 transduced cells, perhaps with CDKN1A involvement. The targeted inhibition of IRF9 in lung cancer could therefore be used as a new treatment option without multimodal interference in microenvironment JAK-STAT signaling.
Background: We analyzed whether co-occurring mutations influence the outcome of systemic therapy in ALK-rearranged non-small-cell lung cancer (NSCLC).
Patients and methods: ALK-rearranged stage IIIB/IV NSCLC patients were analyzed with next-generation sequencing and fluorescence in situ hybridization analyses on a centralized diagnostic platform. Median progression-free survival (PFS) and overall survival (OS) were determined in the total cohort and in treatment-related sub-cohorts. Cox regression analyses were carried out to exclude confounders.
Results: Among 216 patients with ALK-rearranged NSCLC, the frequency of pathogenic TP53 mutations was 23.8%, while other co-occurring mutations were rare events. In ALK/TP53 co-mutated patients, median PFS and OS were significantly lower compared with TP53 wildtype patients [PFS 3.9 months (95% CI: 2.4–5.6) versus 10.3 months (95% CI: 8.6–12.0), P < 0.001; OS 15.0 months (95% CI: 5.0–24.9) versus 50.0 months (95% CI: 22.9–77.1), P = 0.002]. This difference was confirmed in all treatment-related subgroups including chemotherapy only [PFS first-line chemotherapy 2.6 months (95% CI: 1.3–4.1) versus 6.2 months (95% CI: 1.8–10.5), P = 0.021; OS 2.0 months (95% CI: 0.0–4.6) versus 9.0 months (95% CI: 6.1–11.9), P = 0.035], crizotinib plus chemotherapy [PFS crizotinib 5.0 months (95% CI: 2.9–7.2) versus 14.0 months (95% CI: 8.0–20.1), P < 0.001; OS 17.0 months (95% CI: 6.7–27.3) versus not reached, P = 0.049] and crizotinib followed by next-generation ALK-inhibitor [PFS next-generation inhibitor 5.4 months (95% CI: 0.1–10.7) versus 9.9 months (95% CI: 6.4–13.5), P = 0.039; OS 7.0 months versus 50.0 months (95% CI: not reached), P = 0.001).
Conclusions: In ALK-rearranged NSCLC co-occurring TP53 mutations predict an unfavorable outcome of systemic therapy. Our observations encourage future research to understand the underlying molecular mechanisms and to improve treatment outcome of the ALK/TP53 co-mutated subgroup.
The nuclear factor kappa beta (NFκB) signaling pathway plays an important role in liver homeostasis and cancer development. Tax1-binding protein 1 (Tax1BP1) is a regulator of the NFκB signaling pathway, but its role in the liver and hepatocellular carcinoma (HCC) is presently unknown. Here we investigated the role of Tax1BP1 in liver cells and murine models of HCC and liver fibrosis. We applied the diethylnitrosamine (DEN) model of experimental hepatocarcinogenesis in Tax1BP1+/+ and Tax1BP1−/− mice. The amount and subsets of non-parenchymal liver cells in in Tax1BP1+/+ and Tax1BP1−/− mice were determined and activation of NFκB and stress induced signaling pathways were assessed. Differential expression of mRNA and miRNA was determined. Tax1BP1−/− mice showed increased numbers of inflammatory cells in the liver. Furthermore, a sustained activation of the NFκB signaling pathway was found in hepatocytes as well as increased transcription of proinflammatory cytokines in isolated Kupffer cells from Tax1BP1−/− mice. Several differentially expressed mRNAs and miRNAs in livers of Tax1BP1−/− mice were found, which are regulators of inflammation or are involved in cancer development or progression. Furthermore, Tax1BP1−/− mice developed more HCCs than their Tax1BP1+/+ littermates. We conclude that Tax1BP1 protects from liver cancer development by limiting proinflammatory signaling.
Objective: To evaluate prognostic factors in pediatric patients with gonadal germ cell tumors (GCT). Methods: Patients <18 years with ovarian and testicular GCT (respectively OGCT and TGCT) were prospectively registered according to the guidelines of MAKEI 96. After resection of the primary tumor, patients staged ≥II received risk-stratified cisplatin-based combination chemotherapy. Patients were analyzed in respect to age (six age groups divided into 3-year intervals), histology, stage, and therapy. The primary end point was overall survival. Results: Between January 1996 and March 2016, the following patients were registered: 1047 OGCT, of those, 630 had ovarian teratoma (OTER) and 417 had malignant OGCT (MOGCT); and 418 TGCT, of those, 106 had testicular teratoma (TTER) and 312 had malignant TGCT (MTGCT). Only in MTGCT, older age correlated with a higher proportion of advanced tumors. All 736 teratomas and 240/415 stage I malignant gonadal GCT underwent surgery and close observation alone. In case of watchful waiting, the progression rate of OGCT was higher than that of TGCT. However, death from disease was reported in 8/417 (1.9%) MOGCT and 8/312 (2.6%) MTGCT irrespective of adjuvant chemotherapy and repeated surgery. Conclusions: The different pathogenesis and histogenesis of gonadal GCT reflects sex- and age-specific patterns that define clinically relevant risk groups. Therefore, gender and age should be considered in further research on the biology and clinical practice of pediatric gonadal GCT.